4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Biotechnology

Healthcare
$10.46 +1.70%

+$0.16 today

Market cap
$577.85M
Beta
2.76
P/E (TTM)
-4.0
EPS (TTM)
-$2.36
52W Low $3.68High $12.34

Volume 0.68M

Average 0.77M

FDMT Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

4D Molecular Therapeutics, Inc.NASDAQ: FDMT

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $4.45M fell 36.3% year over year, behind the -28.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 19.8% from the prior quarter. Over 3 fiscal years it compounded at +8.7% a year.

Context

  • Stock-based compensation amounted to 25.8% of revenue in FY2025, down 70557.9 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -36.3% toward the trailing-twelve-month pace of -28.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.45M-19.8% QoQ
Last fiscal yearDec 2025
$22.02M-15.7% YoY
LTMMar 2026
$19.48M-28.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.3%——
1 year-15.7%——
3-year CAGR+8.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
22.02M USD
Year-over-year change
-15.7%
4-year CAGR
+12.4%

Stock-Based Compensation vs competitors

How FDMT compares with its peers on the latest reported figures

  • FDMT's LTM Mar 2026 stock-based compensation of $19.48M is the 3rd largest of the 8 companies compared; the peer median is $18.36M.
  • Its year-over-year change of -28.2% is the lowest of 8, against a peer median of +7.1%.
  • Stock-based compensation amounts to 22.1% of revenue for FDMT, versus a peer median of 60.1%.
FDMT Competitors Peer median
Stock-Based Compensation for FDMT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGTXMeiraGTx Holdings plcLTM Mar 2026$47.93M +107.3%-8.3%60.1%
RGNXREGENXBIO Inc.LTM Mar 2026$34.64M -7.4%-5.4%39.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$19.48M -28.2%+8.7%22.1%
SLDBSolid Biosciences Inc.LTM Mar 2026$18.73M +52.9%+30.9%—
QUREuniQure N.V.LTM Mar 2026$18.36M -5.7%-19.7%101.5%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$11.19M -19.1%+89.6%—
OCGNOcugen, Inc.LTM Mar 2026$9.22M +22.1%-9.9%206.5%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$8.33M +7.1%+52.3%57.3%
Peer median (excluding FDMT) $18.36M+7.1%-5.4%60.1%

Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Depreciation & Amortization3.02M3.88M5.75M6.71M7.63M
Deferred Income Tax00000
Stock-Based Compensation13.8M17.12M19.67M26.12M22.02M
Change in Working Capital(15.53M)(1.34M)630K537K6.17M
Accounts Receivables1.44M47K000
Inventory(4.54M)0000
Accounts Payables2.29M(1.64M)896K871K6.77M
Other Working Capital(14.72M)255K(266K)(334K)(601K)
Other Non-Cash Items898K1.14M(999K)(7.08M)(4.79M)
Operating Cash Flow(69.13M)(86.69M)(75.79M)(134.59M)(109.08M)
Capital Expenditures(9.11M)(11.54M)(2.77M)(3.79M)(536K)
Acquisitions (Net)9.11M0000
Purchases of Investments(168.57M)(153.31M)(54.8M)(467.65M)(442.82M)
Sales of Investments5M147.8M173.29M169M350.38M
Other Investing Activities(9.11M)0173.29M00
Investing Cash Flow(172.68M)(17.05M)115.72M(302.44M)(92.97M)
Debt Repayment00000
Common Stock Issued114.3M3.09M148.34M331.41M112.96M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.79M08.49M5.84M0
Financing Cash Flow118.09M3.09M156.83M337.25M112.96M
Effect of Forex Changes00000
Net Change in Cash(123.73M)(100.65M)196.76M(99.77M)(89.1M)
Free Cash Flow(78.24M)(98.22M)(78.56M)(138.37M)(109.08M)

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Intrinsic Alpha fair value

Locked

Current Price

$10.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.